Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 140Leukemia 132Lymphoma 90Leukemia, Myeloid, Acute 62Myelodysplastic Syndromes 47Burkitt Lymphoma 46Lymphoma, Non-Hodgkin 44Lymphoma, Large B-Cell, Diffuse 37Breast Neoplasms 37Lymphoma, Mantle-Cell 33Leukemia, Lymphocytic, Chronic, B-Cell 33Hodgkin Disease 32Multiple Myeloma 29Congenital Abnormalities 29Myeloproliferative Disorders 27Lymphoma, Follicular 27Leukemia, Myeloid, Accelerated Phase 27Graft vs Host Disease 27Leukemia, Myelomonocytic, Chronic 25Lymphoma, Large-Cell, Immunoblastic 24Leukemia, Myeloid, Chronic-Phase 24Blast Crisis 24Lymphoma, B-Cell, Marginal Zone 22Leukemia, Myelogenous, Chronic, BCR-ABL Positive 20Anemia, Refractory, with Excess of Blasts 20Recurrence 18Primary Myelofibrosis 17Neoplasms, Plasma Cell 17Dendritic Cell Sarcoma, Interdigitating 17Osteosarcoma 16

Interventions

Alemtuzumab 2tocilizumab 1Whole-Body Irradiation 1Polymerase Chain Reaction 1Methotrexate 1In Situ Hybridization 1Immunohistochemistry 1Flow Cytometry 1Etoposide 1Emapalumab 1Dexamethasone 1Data Collection 1Cytogenetic Analysis 1Cytarabine 1Cyclophosphamide 1Calcium Dobesilate 1Blotting, Western 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphohistiocytosis, Hemophagocytic × Methotrexate × Clear all
NCT02385110 2024-01-17

Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis

M.D. Anderson Cancer Center

Phase 2 Completed
18 enrolled 10 charts
MyeloidOther hematologic neoplasm

Leukemia, Lymphohistiocytosis, Hemophagocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡